Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers.
| Condition | Intervention | Phase |
|---|---|---|
|
Candidiasis |
Drug: Fluconazole Loading Dose Drug: Fluconazole Loading Dose & High Dose |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers |
- Plasma concentration of Fluconazole [ Time Frame: 6-8 samples over 5 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 13 |
| Study Start Date: | November 2008 |
| Study Completion Date: | September 2011 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Loading Dose
Loading Dose
|
Drug: Fluconazole Loading Dose
Single Fluconazole loading dose 25 mg/kg
Other Name: Diflucan
|
|
Loading & high dose
Loading dose & high dose Fluconazole
|
Drug: Fluconazole Loading Dose & High Dose
Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
Other Name: Diflucan
|
Detailed Description:
This is an open label study to investigative the pharmacokinetics and safety of a fluconazole loading dose in infants and toddlers < 2 years of age with suspected sepsis. There will be two treatment groups: single fluconazole loading dose 25 mg/kg; fluconazole loading dose 25mg/kg followed by 12 mg/kg daily for total of 5 days. There will be three age cohorts within each group: pre-term < 30 week EGA infants > 48 hours and < 31 days; > 30 weeks EGA infants > 48 hours and < 31 days; infants ≥ 31 days and < 2 years of age. The study requires administration of fluconazole over 1-5 days depending on treatment group followed by 1 week of safety monitoring. Six to eight 100 µL PK samples will be obtained over the 5 days of drug administration. The risks are reasonable vs. the benefits and have been minimized appropriately. There may be benefit to the subjects (administration of empirical antifungal therapy), and information from the study may benefit a large number of other infants and toddlers with suspected or proven fungal sepsis. There is a data analysis plan.
Eligibility| Ages Eligible for Study: | up to 2 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- suspected sepsis with blood culture within 48 hours
- age ≥ 48 hours and < 2 years of age
- sufficient venous access to permit study drug administration
Exclusion Criteria:
- allergic reaction to azole
- history of fluconazole administration in prior 5 days
- liver dysfunction
- renal failure
- concomitant use of cyclosporine, tacrolimus, or azithromycin
Contacts and Locations| United States, North Carolina | |
| Duke Univeristy Medical Center | |
| Durham, North Carolina, United States, 27715 | |
| Principal Investigator: | Lauren Piper, MD | Duke University |
More Information
Publications:
| Responsible Party: | Daniel Benjamin, Professor of Pediatrics, Duke University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00797420 History of Changes |
| Other Study ID Numbers: | Pro00011454, NIH-5U10-HD-045962-04 |
| Study First Received: | November 23, 2008 |
| Last Updated: | March 18, 2013 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Duke University:
|
fluconazole pharmacokinetic candidiasis sepsis pediatric |
infants antifungal candidemia fungemia loading dose |
Additional relevant MeSH terms:
|
Candidiasis Mycoses Fluconazole Antifungal Agents Anti-Infective Agents |
Therapeutic Uses Pharmacologic Actions 14-alpha Demethylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013